home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410p.zip
/
M94A3051.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
35 lines
Document 3051
DOCN M94A3051
TI Activated CD8-cells--a new surrogate marker?
DT 9412
AU Hoffmann UJ; Mischo M; Reichelt D; Busch H; Zidek W; Medizinische
Poliklinik, University of Munster, Germany.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):165 (abstract no. PB0087). Unique
Identifier : AIDSLINE ICA10/94369524
AB OBJECTIVE: To determine the usefullness of CD38+CD8+ and HLA-DR+CD8+
cells for monitoring of antiretroviral therapy. METHODS: HIV infected
patients who started or changed an antiretroviral therapy were
controlled for lymphocyte subsets, beta 2-microglobulin, p24 antigen and
antibodies, and immunoglobulins at baseline and after 1, 2, 3, and 6
months. RESULTS: The expression of CD38+CD8+ and HLA-DR+CD8+ lymphoid
phenotypic markers is increased after 1 month of zidovudine (ZDV)
therapy with subsequent decrease. With didanosine (ddI) monotherapy only
slight changes of these markers could be detected. Patients on
combination therapy with ZDV and zalcitabine (ddC) showed an initial
decrease of the number of CD38+CD8+ cells followed by an increase.
Similar results were found for HLA-DR+CD8+ cells. CONCLUSIONS: The
number of CD38+CD8+ and HLA-DR+CD8+ cells is modulated by antiretroviral
therapy. The kind of modulation seems to be dependent on the choice of
the nucleosid analogon.
DE Antigens, CD8/*BLOOD Antigens, Differentiation/*BLOOD
Didanosine/ADMINISTRATION & DOSAGE Drug Therapy, Combination Follow-Up
Studies Human HIV Infections/DRUG THERAPY/*IMMUNOLOGY HLA-DR
Antigens/*BLOOD Leukocyte Count/DRUG EFFECTS Lymphocyte
Transformation/DRUG EFFECTS/*IMMUNOLOGY T-Lymphocyte Subsets/DRUG
EFFECTS/*IMMUNOLOGY Zalcitabine/ADMINISTRATION & DOSAGE
Zidovudine/ADMINISTRATION & DOSAGE MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).